Target intelligence / Profile preview

RNA, U2 small nuclear 33, pseudogene (RNU2-33P)

Target
RNU2-33P
Molecular classification
Other (Pseudogene), Non-coding RNA (pseudogene of small nuclear RNA)
01

Overview

RNA, U2 small nuclear 33, pseudogene (RNU2-33P) is a member of the U2 snRNA pseudogene family. Pseudogenes are genomic DNA sequences similar to normal genes but nonfunctional; they typically do not encode functional RNA or protein products. The U2 small nuclear RNA family is a critical component of the spliceosome involved in pre-mRNA splicing, but pseudogenes like RNU2-33P are classified as nonfunctional remnants with no known biological activity[1]. There is no evidence that RNU2-33P is transcribed, participates in splicing, or is associated with human disease or therapeutics. It is not considered a therapeutic target, nor does it have any reported function as a biomarker or drug interaction partner. RNU2-33P is a pseudogene, meaning it is not a functional gene product, not a protein, enzyme, or true receptor, nor an established drug or biomarker target. This distinguishes it from functional U2 snRNAs (such as RNU2-1 or the reclassified RNU2-2), which are essential for spliceosome assembly and have emerging disease associations[4][5]. RNU2-33P is essentially a genomic fossil of U2 snRNA, annotated historically due to sequence similarity with the parent gene[1].

Other names
RNU2-33PU2 snRNA pseudogene 33RNA, U2 small nuclear pseudogene 33
02

Biological functions

Other (no known function; not transcribed or functional)
03

Disease associations

Other (no established disease role)

Beyond the preview

Go deeper on RNA, U2 small nuclear 33, pseudogene (RNU2-33P).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNA, U2 small nuclear 33, pseudogene (RNU2-33P).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call